The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
Single‐Dose and Steady‐State Pharmacokinetics and Pharmacodynamics of Perindopril in Hypertensive Subjects
Summary : In a double-blind , placebo-controlled , parallel group study , 24 essential hypertensive subjects were r and omised to receive either placebo or 2 , 4 , or 8 mg perindopril . Perindopril , its deesterified metabolite , perindoprilat , and perindoprilat glucuronide were separated with an ion-exchange resin and determined by a radioimmunoassay ( RIA ) . Pharmacokinetic and pharmacodynamic parameters were estimated for 96 h after the first dose and after 4-week once-daily treatment . Perindopril peak levels were achieved in < 2 h after dosing with an elimination t1/2 of 1–2 h. Peak levels of perindoprilat were achieved more slowly , reaching a maximum level 5–8 h after dosing , and had an elimination t1/2 of 40 h. Levels of the perindopril glucuronide peaked ∼0.5 h later than perindopril , with an elimination t1/2 of ∼2 h. Perindopril , perindoprilat , and its glucuronide conjugate followed linear kinetics in the dose range of 2–8 mg , and there was no evidence of accumulation with chronic dosing . Perindopril 4 and 8 mg produced significant decreases in pre-dose blood pressure ( BP ) with chronic dosing , with maximal decreases occurring 5–7 h after dosing . Perindopril also produced a prolonged dose-dependent inhibition of plasma angiotensin-converting enzyme ( ACE ) activity that was maximum after 4 h and had not fully recovered by 48 h after a single dose
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .